These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium. Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938 [TBL] [Abstract][Full Text] [Related]
6. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065 [TBL] [Abstract][Full Text] [Related]
7. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934 [TBL] [Abstract][Full Text] [Related]
8. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related]
9. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
10. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508 [TBL] [Abstract][Full Text] [Related]
11. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study. Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383 [TBL] [Abstract][Full Text] [Related]
12. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Kontorovich T; Cohen Y; Nir U; Friedman E Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075 [TBL] [Abstract][Full Text] [Related]
13. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Meisel JL; Hyman DM; Garg K; Zhou Q; Dao F; Bisogna M; Gao J; Schultz ND; Grisham RN; Phillips M; Iasonos A; Kauff ND; Levine DA; Soslow RA; Spriggs DR Ann Oncol; 2014 Dec; 25(12):2372-2378. PubMed ID: 25281711 [TBL] [Abstract][Full Text] [Related]
14. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852 [TBL] [Abstract][Full Text] [Related]
15. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma. Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506 [TBL] [Abstract][Full Text] [Related]